Hyaluronic acid-engineered Bcl-2 inhibitor nanocrystals for site-specific delivery to breast tumor cells

被引：3
|
作者：
Panwar, Dilip [1 ]
Thakor, Pradip [1 ]
Sharma, Madhu [2 ]
Bakshi, Avijit Kumar [2 ]
Bhavana, Valamla [1 ]
Srivastava, Vaibhavi [1 ]
Mishra, Prabhat Ranjan [2 ]
Singh, Shashi Bala [3 ]
Mehra, Neelesh Kumar [1 ]
机构：
[1] Natl Inst Pharmaceut Educ & Res NIPER, Dept Pharmaceut, Pharmaceut Nanotechnol Res Lab, Hyderabad 500037, Telangana, India
[2] Council Sci & Ind Res Cent Drug Res Inst CSIR CDRI, Div Pharmaceut, Lucknow 226017, Uttar Pradesh, India
[3] Natl Inst Pharmaceut Educ & Res NIPER, Dept Biol Sci, Hyderabad 500037, Telangana, India
来源：
NANOMEDICINE | 2023年 / 18卷 / 15期
关键词：
breast cancer; glycosaminoglycan; hyaluronic acid; nanocrystals; repurposing; venetoclax; DRUG-DELIVERY; NANOPARTICLES; DOXORUBICIN; PACLITAXEL; PH;
D O I：
10.2217/nnm-2023-0132
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: This investigation aims to repurpose venetoclax using hyaluronic acid-coated venetoclax nanocrystals (HA-VEN-NCs) to target breast cancer. Materials & methods: An antisolvent precipitation method was used to fabricate the nanocrystals and optimize them using central composite design. Hyaluronic acid (HA)-coated and -uncoated nanocrystals were compared in terms of in vitro drug release, cell line studies, CD44-expressing breast tumor cell binding capability and anticancer activity. Results: HA-VEN-NCs and venetoclax nanocrystals (VEN-NCs) showed pH-responsive drug-release behavior, exhibiting sustained release at pH 6.8. Our extensive in vitro cell line investigation showed that HA-VEN-NCs efficiently bind to CD44-expressing breast tumor cells and possess excellent anticancer activity (half maximal inhibitory concentration: 2.00 & mu;g/ml) compared with VEN-NCs. Conclusion: Our findings anticipate that HA-VEN-NCs could serve as valuable nanoplatforms for cancer treatments in the future.
引用
收藏
页码：1005 / 1023
页数：19
相关论文
共 50 条
  • [21] Apoptosis and Bcl-2 expression in circulating tumor cells (CTC) from women being treated for metastatic breast cancer
    Smerage, J. B.
    Doyl, G. V.
    Budd, T.
    Schott, A. F.
    Blayney, D. W.
    Wicha, M. S.
    Repollet, M.
    Terstappen, L.
    Hayes, D. F.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2007, 22 (01): : 81 - 81
  • [22] Apoptosis and Bcl-2 expression in circulating tumor cells from women being treated for metastatic breast cancer.
    Smerage, J. B.
    Doyle, G., V
    Budd, G. T.
    Wicha, M. S.
    Schott, A. F.
    Blayney, D. W.
    Repollet, M.
    Terstappen, L. W. M. M.
    Hayes, D. F.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S214 - S214
  • [23] Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: A comparison between different formulations
    Meidan, VM
    Glezer, J
    Salomon, S
    Sidi, Y
    Barenholz, Y
    Cohen, JS
    Lilling, G
    JOURNAL OF LIPOSOME RESEARCH, 2006, 16 (01) : 27 - 43
  • [24] Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells
    Arisan, Elif Damla
    Kutuk, Ozgur
    Tezil, Tugsan
    Bodur, Cagri
    Telci, Dilek
    Basaga, Huveyda
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (02) : 271 - 281
  • [25] Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2
    Real, PJ
    Cao, YY
    Wang, RX
    Nikolovska-Coleska, Z
    Sanz-Ortiz, J
    Wang, SM
    Fernandez-Luna, JL
    CANCER RESEARCH, 2004, 64 (21) : 7947 - 7953
  • [26] Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells
    Elif Damla Arisan
    Ozgur Kutuk
    Tugsan Tezil
    Cagri Bodur
    Dilek Telci
    Huveyda Basaga
    Breast Cancer Research and Treatment, 2010, 119 : 271 - 281
  • [27] Upregulation of proapoptotic and downregulation of antiapoptotic Bcl-2 proteins by diclophenac/hyaluronic acid gel in cutaneous SCC cells trigger the mitochondrial apoptosis pathway
    Rodust, P. M.
    Stockfleth, E.
    Fecker, L. F.
    Eberle, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 (09): : 846 - 846
  • [28] The detection of apoptosis and Bcl-2 expression in circulating tumor cells (CTCs) from women being treated for metastatic breast cancer
    Smerage, Jeffrey B.
    Doyle, Gerald V.
    Budd, G. Thomas
    Schott, Anne F.
    Blayney, Douglas W.
    Wicha, Max S.
    Repollet, Madeline
    Terstappen, Leon W. M. M.
    Hayes, Daniel F.
    CANCER RESEARCH, 2006, 66 (08)
  • [29] Single-Domain Protein A-Engineered Magnetic Nanoparticles: Toward a Universal Strategy to Site-Specific Labeling of Antibodies for Targeted Detection of Tumor Cells
    Mazzucchelli, Serena
    Colombo, Miriam
    De Palma, Clara
    Salvade, Agnese
    Verderio, Paolo
    Coghi, Maria D.
    Clementi, Emilio
    Tortora, Paolo
    Corsi, Fabio
    Prosperi, Davide
    ACS NANO, 2010, 4 (10) : 5693 - 5702
  • [30] CELL-PERMEABLE PEPTIDES COVERING THE NIP-RECOGNITION SITE OF BCL-2 AND BCL-2 SPECIFIC HAMMERHEAD RIBOZYMES RESTORE SENSITIVITY OF MULTIPLE-MYELOMA CELLS TO GLUCOCORTICOID-INDUCED APOPTOSIS
    KIEHNTOPF, M
    HERRMANN, F
    BRACH, MA
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 905 - 905
12345